Tibotec

Tibotec
Industry	Pharmaceutical
Founded	1994; 30 years ago
Founders	Rudi Pauwels; Carine Claeys; Marie-Pierre de Béthune; Kurt Hertogs; Hilde Azijn;
Defunct	2002
Fate	Acquired by Johnson & Johnson and merged into its Janssen Pharmaceuticals division
Website	tibotec.com

Tibotec was a pharmaceutical company with a focus on research and development of the treatment of infectious diseases such as HIV/AIDS and hepatitis C. The company was founded in 1994 and then acquired by Johnson & Johnson and merged into its Janssen Pharmaceuticals division in 2002.

The name of the company is derived from the tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and -thione (TIBO) compounds discovered at the Rega Institute for Medical Research (Belgium).^[1]

^ Pauwels, Rudi; Andries, Koen; Desmyter, Jan; Schols, Dominique; Kukla, Michael J.; Breslin, Henry J.; Raeymaeckers, Alfons; Gelder, Jozef Van; Woestenborghs, Robert; Heykants, Jozef; Schellekens, Karel; Janssen, Marcel A. C.; Clercq, Erik De; Janssen, Paul A. J. (1990). "Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives". Nature. 343 (6257): 470–474. Bibcode:1990Natur.343..470P. doi:10.1038/343470a0. PMID 1689015. S2CID 4354080.

[1] Pauwels, Rudi; Andries, Koen; Desmyter, Jan; Schols, Dominique; Kukla, Michael J.; Breslin, Henry J.; Raeymaeckers, Alfons; Gelder, Jozef Van; Woestenborghs, Robert; Heykants, Jozef; Schellekens, Karel; Janssen, Marcel A. C.; Clercq, Erik De; Janssen, Paul A. J. (1990). "Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives". Nature. 343 (6257): 470–474. Bibcode:1990Natur.343..470P. doi:10.1038/343470a0. PMID 1689015. S2CID 4354080.

[1]